Anika Therapeutics Inc. (ANIK)

44.41
0.39 0.87
NASDAQ : Health Technology
Prev Close 44.80
Open 44.75
Day Low/High 44.11 / 45.15
52 Wk Low/High 42.51 / 69.81
Volume 132.56K
Avg Volume 98.90K
Exchange NASDAQ
Shares Outstanding 14.74M
Market Cap 660.72M
EPS 2.20
P/E Ratio 21.24
Div & Yield N.A. (N.A)

Latest News

Joseph Darling Named CEO And Director Of Anika Therapeutics

Joseph Darling Named CEO And Director Of Anika Therapeutics

Dr. Charles Sherwood to retire after 20 years of innovation and leadership at the Company

Anika Reports Fourth Quarter And Full Year 2017 Financial Results

Anika Reports Fourth Quarter And Full Year 2017 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika To Issue Fourth-Quarter 2017 Financial Results And Business Highlights On Wednesday, February 21

Anika To Issue Fourth-Quarter 2017 Financial Results And Business Highlights On Wednesday, February 21

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference...

Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology At The University Of Liverpool To Develop An Innovative Therapy For Osteoarthritis

Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology At The University Of Liverpool To Develop An Innovative Therapy For Osteoarthritis

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced an agreement with...

Anika Therapeutics Expands Strategic Collaboration With The Institute For Applied Life Sciences (IALS) At The University Of Massachusetts Amherst To Develop Innovative Therapy For Rheumatoid Arthritis

Anika Therapeutics Expands Strategic Collaboration With The Institute For Applied Life Sciences (IALS) At The University Of Massachusetts Amherst To Develop Innovative Therapy For Rheumatoid Arthritis

A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc.

Anika Announces FDA 510(k) Clearance For Its Injectable HA-Based Bone Repair Treatment

Anika Announces FDA 510(k) Clearance For Its Injectable HA-Based Bone Repair Treatment

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its HA-based...

Anika Therapeutics Enters Oversold Territory (ANIK)

Anika Therapeutics Enters Oversold Territory (ANIK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Anika Reports Third Quarter 2017 Financial Results

Anika Reports Third Quarter 2017 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Completes Enrollment In Second Pivotal Phase III Trial Of CINGAL For The Treatment Of Knee Pain Associated With Osteoarthritis

Anika Completes Enrollment In Second Pivotal Phase III Trial Of CINGAL For The Treatment Of Knee Pain Associated With Osteoarthritis

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the completion of...

Anika Announces The Forthcoming Appointment Of Thomas M. Finnerty As Chief Human Resources Officer

Anika Announces The Forthcoming Appointment Of Thomas M. Finnerty As Chief Human Resources Officer

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of...

Anika Announces Regulatory Approval For MONOVISC® In Australia For The Treatment Of Pain Associated With Osteoarthritis Of All Synovial Joints

Anika Announces Regulatory Approval For MONOVISC® In Australia For The Treatment Of Pain Associated With Osteoarthritis Of All Synovial Joints

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory...

Anika To Issue Third-Quarter 2017 Financial Results And Business Highlights On Wednesday, October 25

Anika To Issue Third-Quarter 2017 Financial Results And Business Highlights On Wednesday, October 25

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference...

Anika Announces Appointment Of Steven Chartier As Vice President Of Regulatory And Clinical Affairs

Anika Announces Appointment Of Steven Chartier As Vice President Of Regulatory And Clinical Affairs

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of...

Anika Announces Publication Of Data Demonstrating The Efficacy And Safety Of HYALOFAST® In Combination With Stem Cells For The Treatment Of Cartilage Lesions On The Knee

Anika Announces Publication Of Data Demonstrating The Efficacy And Safety Of HYALOFAST® In Combination With Stem Cells For The Treatment Of Cartilage Lesions On The Knee

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the publication of...

Anika Announces Appointment Of Joseph Darling As President

Anika Announces Appointment Of Joseph Darling As President

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of...

Anika Reports Strong Second Quarter 2017 Financial Results

Anika Reports Strong Second Quarter 2017 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Announces Regulatory Approval For MONOVISC® In India For The Treatment Of Pain Associated With Osteoarthritis Of All Synovial Joints

Anika Announces Regulatory Approval For MONOVISC® In India For The Treatment Of Pain Associated With Osteoarthritis Of All Synovial Joints

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory...

Anika Announces $5 Million Milestone Payment From U.S. Commercial Sales Of MONOVISC

Anika Announces $5 Million Milestone Payment From U.S. Commercial Sales Of MONOVISC

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it will...

Anika To Issue Second-Quarter 2017 Financial Results And Business Highlights On Wednesday, July 26

Anika To Issue Second-Quarter 2017 Financial Results And Business Highlights On Wednesday, July 26

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2017 financial results after the close of the market on Wednesday, July 26, 2017 and to hold a conference call...

Anika To Present At The Singular Research Summer Solstice Conference On July 13, 2017

Anika To Present At The Singular Research Summer Solstice Conference On July 13, 2017

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President...

Here Comes a Big Breakout For Alibaba

Here Comes a Big Breakout For Alibaba

What the charts say.

Anika Announces Data Presentation And Symposium On CINGAL At 2017 EFORT Annual Congress

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to present...

Anika Announces First Patient Enrolled In Supplemental Phase III Trial Of CINGAL For The Treatment Of Knee Pain Associated With Osteoarthritis

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the enrollment of...

Anika Celebrates 25th Anniversary And Inaugurates Newly Expanded And Consolidated Global Manufacturing Facility In Bedford, Massachusetts

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, is hosting a celebration today at...

Anika Announces Publication Of Phase III Data Demonstrating The Efficacy And Safety Of CINGAL® For The Treatment Of Knee Pain Associated With Osteoarthritis

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the publication of...

Biotech Movers: Anika Up on Strong Analyst Ratings

Biotech Movers: Anika Up on Strong Analyst Ratings

Anika focuses on pain management, tissue regeneration and wound healing.

TheStreet Quant Rating: B- (Buy)